Arvind Kush Buys 145,000 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) Stock

Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush bought 145,000 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were acquired at an average price of $1.37 per share, with a total value of $198,650.00. Following the purchase, the director now owns 145,000 shares in the company, valued at $198,650. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Inhibikase Therapeutics Stock Up 3.7 %

Inhibikase Therapeutics stock opened at $2.52 on Friday. The business has a 50 day moving average price of $1.44 and a two-hundred day moving average price of $1.53. The stock has a market cap of $18.18 million, a price-to-earnings ratio of -0.76 and a beta of 1.32. Inhibikase Therapeutics, Inc. has a 12 month low of $0.80 and a 12 month high of $3.82.

Inhibikase Therapeutics (NYSE:IKT) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). On average, analysts expect that Inhibikase Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their target price on Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, October 14th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inhibikase Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 589,575 shares of the company’s stock, valued at approximately $713,000. Armistice Capital LLC owned about 8.17% of Inhibikase Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.